The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) has approved centanafadine (SIMTRIYO), a norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit/hyperactivity disorder (ADHD).
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) accepted Axsome Therapeutics’ New Drug Application (NDA) for AXS-12 (reboxetine) for cataplexy in narcolepsy.
The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s Magnetic EEG-guided Resonance Therapy (MeRT) System, a biomarker-guided neuromodulation technology for the treatment of posttraumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s Magnetic EEG-guided Resonance Therapy (MeRT) System, a biomarker-guided neuromodulation technology for the treatment of posttraumatic stress disorder (PTSD).
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
Following an April 18 executive order, the US Food and Drug Administration (FDA) announced new regulatory actions to accelerate the development of psychedelic-assisted therapy for mental health conditions.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for lumateperone (CAPLYTA) for relapse prevention in schizophrenia.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A self-led digital intervention targeting repetitive negative thinking significantly reduced anxiety during pregnancy and after childbirth, according to recent findings.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
A single administration of mebufotenin benzoate nasal spray produced rapid, sustained reductions in depressive symptoms among adults with TRD, according to a phase 2b trial published in JAMA.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Investigational RAP-219 met the primary and secondary endpoints in a randomized, double-blind, placebo-controlled trial of adults experiencing acute bipolar mania, manufacturer Rapport Therapeutics announced on October 20, 2026.
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
Home transcranial direct current stimulation paired with cognitive training delivered through a video game was feasible but offered no superior antidepressant benefit in a randomized clinical trial published in JAMA Network Open.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
A connectivity-guided approach to accelerated iTBS produced greater short-term reductions in depression severity than conventional scalp-based targeting.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Young people beginning antipsychotic treatment after first-episode psychosis had low medication adherence, according to a retrospective US cohort study published in JAMA Network Open.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Reducing ultraprocessed food consumption was feasible and acceptable among adults with major depressive disorder (MDD) and was associated with lower depression and anxiety scores.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Melanie Barrett, MD, discusses how mental health care providers can address gaps in postpartum depression screening, diagnosis, and treatment in clinical practice.
Melanie Barrett, MD, discusses how mental health care providers can address gaps in postpartum depression screening, diagnosis, and treatment in clinical practice.
Mariela Podolski, MD; James C. Somers, DHSc, PA-C, DFAAPA
Psych Congress faculty members Mariela Podolski, MD, and James Somers, PA-C, DHSc, DFAAPA, discuss the relationship between nutrition and psychiatric outcomes.
Psych Congress faculty members Mariela Podolski, MD, and James Somers, PA-C, DHSc, DFAAPA, discuss the relationship between nutrition and psychiatric outcomes.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Psych Congress PA Institute Co-Chair Kevin Williams, MS, MPAS, PA-C, explores how clinicians may incorporate the caregiver perspective into TD treatment, particularly when patients are unaware of their symptoms.
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
Michael Asbach, DMSc, PA-C, Clinical Editor, Psych Congress Journal, explores key concepts from his Psych Congress 2026 session, “Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?”
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
The Dr Vladimir Maletic Memorial Scholarship was established to honor the life, legacy, and lasting influence of Dr Vladimir Maletic, a beloved member of the Psych Congress community and exceptional clinician and educator.
Julie Carbray PhD, PMHNP-BC, PMHCNS-BC, FAAN; James Greenblatt, MD
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Julie Carbray, PhD, PMHNP-BC, FAAN, and James Greenblatt, MD, discuss how functional impairment, symptom severity, patient preferences, life stage, and family perspectives can shape initial ADHD treatment decisions, as explored at their 2026...
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
According to an interview with Rakesh Jain, MD, MPH, what is a common mistake clinicians make when evaluating sleep complaints in patients with psychiatric disorders?
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Arwen Podesta, MD, DFAPA, Psych Congress Steering Committee Member, and Mike Asbach, DMSc, PA-C, Co-Chair, Psych Congress PA Institute, discuss practical strategies for incorporating nutrition and exercise recommendations into psychiatric...
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
Kristian Dambrino, DNP, PMHNP-BC, explores the role that dual-mechanism and multimodal medications may play in individualized major depressive disorder (MDD) care.
